Mini review Special Issues

Dysbiosis, small intestinal bacterial overgrowth and biofilms in autism and chronic illness

  • Received: 28 February 2018 Accepted: 22 May 2018 Published: 07 June 2018
  • Recent evidences highlight that alteration of gut microbiota homeostasis could trigger several human pathologies, among them autism spectrum disorders (ASD). This short hypothesis article summarizes the recent literature and offers a novel, complementary and biomedical drugs/natural agents-combined therapy for treating gastrointestinal issues and microbial biofilms in ASD and chronic illness.

    Citation: Anju Usman Singh. Dysbiosis, small intestinal bacterial overgrowth and biofilms in autism and chronic illness[J]. AIMS Molecular Science, 2018, 5(2): 160-165. doi: 10.3934/molsci.2018.2.160

    Related Papers:

  • Recent evidences highlight that alteration of gut microbiota homeostasis could trigger several human pathologies, among them autism spectrum disorders (ASD). This short hypothesis article summarizes the recent literature and offers a novel, complementary and biomedical drugs/natural agents-combined therapy for treating gastrointestinal issues and microbial biofilms in ASD and chronic illness.


    加载中
    [1] Cryan JF, Dinan TG (2012) Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13: 701–712. doi: 10.1038/nrn3346
    [2] Borre YE, Moloney RD, Clarke G, et al. (2014) The impact of microbiota on brain and behavior: Mechanisms & therapeutic potential. Adv Exp Med Biol 817: 373–403. doi: 10.1007/978-1-4939-0897-4_17
    [3] Diagnostic and Statistical Manual of Mental Disorders (DSM-V), 2013. American Psychiatric Association, 189: 4189.
    [4] Siniscalco D, Cirillo A, Bradstreet JJ, et al. (2013) Epigenetic findings in autism: New perspectives for therapy. Int J Environ Res Public Health 10: 4261–4273. doi: 10.3390/ijerph10094261
    [5] Frye RE, Slattery J, Macfabe DF, et al. (2015) Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis 26: 26878.
    [6] De Magistris L, Picardi A, Siniscalco D, et al. (2013) Antibodies against food antigens in patients with autistic spectrum disorders. BioMed Res Int 2013: 729349.
    [7] Mcelhanon BO, Mccracken C, Karpen S, et al. (2014) Gastrointestinal symptoms in autism spectrum disorder: A meta-analysis. Pediatrics 133: 872–883. doi: 10.1542/peds.2013-3995
    [8] Adams JB, Johansen LJ, Powell LD, et al. (2011) Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol 11: 22. doi: 10.1186/1471-230X-11-22
    [9] Nikolov RN, Bearss KE, Lettinga J, et al. (2009) Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 39: 405–413. doi: 10.1007/s10803-008-0637-8
    [10] Iovene MR, Bombace F, Maresca R, et al. (2017) Intestinal dysbiosis and Yeast Isolation in Stool of Subjects with Autism Spectrum Disorders. Mycopathologia 182: 349–363. doi: 10.1007/s11046-016-0068-6
    [11] Siniscalco D (2014) Gut bacteria-brain axis in autism. Autism 4: e124.
    [12] Kranich J, Maslowski KM, Mackay CR (2011) Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol 23: 139–145. doi: 10.1016/j.smim.2011.01.011
    [13] Macfarlane S, Macfarlane GT (2006) Composition and metabolic activities of bacterial biofilms colonizing food residues in the human gut. Appl Environ Microbiol 72: 6204–6211. doi: 10.1128/AEM.00754-06
    [14] Liu Y, Fatheree NY, Mangalat N, et al. (2010) Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299: G1087–G1096. doi: 10.1152/ajpgi.00124.2010
    [15] Fateh R, Iravani S, Frootan M, et al. (2011) Synbiotic preparation in men suffering from functional constipation: A randomised controlled trial. Swiss Med Wkly 141: w13239.
    [16] Vuong HE, Hsiao EY (2017) Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder. Biol Psychiatry 81: 411–423. doi: 10.1016/j.biopsych.2016.08.024
    [17] Strati F, Cavalieri D, Albanese D, et al. (2017) New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome 5: 24. doi: 10.1186/s40168-017-0242-1
    [18] Finegold SM, Molitoris D, Song Y, et al. (2002) Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 35: S6–S16. doi: 10.1086/341914
    [19] Wang L, Christophersen CT, Sorich MJ, et al. (2013) Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder. Mol Autism 4: 42.
    [20] Williams BL, Hornig M, Parekh T, et al. (2012) Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 3: 54–64.
    [21] Kang DW, Park JG, Ilhan ZE, et al. (2013) Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One 8: e68322. doi: 10.1371/journal.pone.0068322
    [22] Ding HT, Taur Y, Walkup JT (2017) Gut microbiota and autism: Key concepts and findings. J Autism Dev Disord 47: 480–489. doi: 10.1007/s10803-016-2960-9
    [23] Frye RE, Nankova B, Bhattacharyya S, et al. (2017) Modulation of immunological pathways in autistic and neurotypical lymphoblastoid cell lines by the enteric microbiome metabolite propionic acid. Front Immunol 8: 1670. doi: 10.3389/fimmu.2017.01670
    [24] Shaw W (2010) Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. Nutr Neurosci 13: 135–143.
    [25] Wang L, Yu YM, Zhang YQ, et al. (2018) Hydrogen breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in autism. Eur Child Adolesc Psychiatry 27: 233–240. doi: 10.1007/s00787-017-1039-2
    [26] Adike A, DiBaise JK (2018) Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management. Gastroenterol Clin North Am 47: 193–208. doi: 10.1016/j.gtc.2017.09.008
    [27] House SA, Goodman DC, Weinstein SJ, et al. (2016) Prescription use among children with autism spectrum disorders in Northern New England: Intensity and small area variation. J Pediatr 169: 277–283. doi: 10.1016/j.jpeds.2015.10.027
    [28] Rana SV, Bhardwaj SB (2008) Small intestinal bacterial overgrowth. Scand J Gastroenterol 43: 1030–1037. doi: 10.1080/00365520801947074
    [29] Quera PR, Quigley EM, Madrid SAM (2005) Small intestinal bacterial overgrowth. An update. Rev Med Chile 133: 1361–1370.
    [30] Gatta L, Scarpignato C (2017) Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 45: 604–616. doi: 10.1111/apt.13928
    [31] Kwiatkowski L, Rice E, Langland J (2017) Integrative treatment of chronic abdominal bloating and pain associated with overgrowth of small intestinal bacteria: A case report. Altern Ther Health Med 23: 56–61.
    [32] Kernien JF, Snarr BD, Sheppard DC, et al. (2018) The interface between fungal biofilms and innate immunity. Front Immunol 8: 1968. doi: 10.3389/fimmu.2017.01968
    [33] Anwar H, Dasgupta MK, Costerton JW (1990) Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 34: 2043–2046. doi: 10.1128/AAC.34.11.2043
    [34] Høiby N, Bjarnsholt T, Moser C, et al. (2015) ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect 1: 1–25.
    [35] Smith A, Buchinsky FJ, Post JC (2011) Eradicating chronic ear, nose, and throat infections: A systematically conducted literature review of advances in biofilm treatment. Otolaryngol Head Neck Surg 144: 338–347. doi: 10.1177/0194599810391620
    [36] Slobodníková L, Fialová S, Rendeková K, et al. (2016) Antibiofilm activity of plant polyphenols. Molecules 21: 1717. doi: 10.3390/molecules21121717
    [37] Li XH, Lee JH (2017) Antibiofilm agents: A new perspective for antimicrobial strategy. J Microbiol 55: 753–766. doi: 10.1007/s12275-017-7274-x
    [38] de Magistris L, Familiari V, Pascotto A, et al. (2010) Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 51: 418–424. doi: 10.1097/MPG.0b013e3181dcc4a5
    [39] Wan MLY, Ling KH, El-Nezami H, et al. (2018) Influence of functional food components on gut health. Crit Rev Food Sci Nutr 2018: 1–10.
    [40] Laparra JM, Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61: 219–225. doi: 10.1016/j.phrs.2009.11.001
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(4217) PDF downloads(3351) Cited by(1)

Article outline

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog